Posted in | News

Weebit Nano and Leti File Two New Patents Optimizing ReRAM Performance

Weebit Nano (ASX: WBT), the Israel-based semiconductor company seeking to develop and commercialize the next generation of memory technology, and its development partner Leti, the French research institute recognized as a global leader in the field of micro-electronics, have filed two new patents for Weebit’s Silicon Oxide (SiOx) ReRAM technology.

Weebit and Leti’s new patents relate to methods for optimizing the performance of ReRAM memory cells by adjusting the manufacturability based on electrical measurements. One patent outlines a general methodology used to achieve the highest electrical performance of ReRAM cells while the other is the specification of that methodology. Identifying the unique SiOx device specification and manufacturing method enhances the commercial viability of Weebit’s technology, and therefore reduces manufacturing costs and allows for more flexible manufacturing capability.

Coby Hanoch, CEO of Weebit Nano, said: “As we move closer to productisation, we are constantly looking for ways to optimize our SiOx ReRAM technology. Our close collaboration with Leti has enabled us to make significant progress and technological breakthroughs, such as the ones covered by these two patents. The precise specification of the optimization process allows us to push the boundaries of ReRAM technology even further and places us at the forefront of the ReRAM industry.”

“While we continue to work on optimizing parameters of Weebit’s ReRAM technology and responding to feedback from potential customers, the latest advancement significantly enhances our manufacturing process and capability ahead of the move to a production fab.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.